Brain Malignancy Steering Committee clinical trials planning workshop: Report from the Targeted Therapies Working Group
Authors:
- B. M. AlexanderBAB. M. Alexander
- E. GalanisEGE. Galanis
- W. K. A. YungWYW. K. A. Yung
- K. V. BallmanKBK. V. Ballman
- J. M. BoyettJBJ. M. Boyett
- T. F. CloughesyTCT. F. Cloughesy
- J. F. DegrootJDJ. F. Degroot
- J. T. HuseJHJ. T. Huse
- B. MannBMB. Mann
- W. MasonWMW. Mason
- I. K. MellinghoffIMI. K. Mellinghoff
- T. MikkelsenTMT. Mikkelsen
- 26 August 2014
- journal article
- review article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 17 (2) , 180-188
Abstract
Glioblastoma is the most common primary brain malignancy and is associated with poor prognosis despite aggressive local and systemic therapy, which is related to a paucity of viable treatment options in both the newly diagnosed and recurrent settings. Even so, the rapidly increasing number of targeted therapies being evaluated in oncology clinical trials offers hope for the future. Given the broad range of possibilities for future trials, the Brain Malignancy Steering Committee convened a clinical trials planning meeting that was held at the Udvar-Hazy Center in Chantilly, Virginia, on September 19 and 20, 2013. This manuscript reports the deliberations leading up to the event from the Targeted Therapies Working Group and the results of the meeting.Keywords
This publication has 43 references indexed in Scilit:
- Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samplesActa Neuropathologica, 2011
- Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolomeProceedings of the National Academy of Sciences, 2011
- Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicineEMBO Molecular Medicine, 2010
- Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of GliomaCancer Cell, 2010
- Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1Cancer Cell, 2010
- Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomideNeuro-Oncology, 2009
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialThe Lancet Oncology, 2009
- An Integrated Genomic Analysis of Human Glioblastoma MultiformeScience, 2008
- Comprehensive genomic characterization defines human glioblastoma genes and core pathwaysNature, 2008
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005